Precipio (formerly Transgenomic) is a biotechnology company advancing personalized medicine for the detection and treatment of cancer and integrated diseases through its proprietary molecular technologies and clinical and research services. The Company develops Multiplexed ICE COLD-PCR (“MX-ICP”) product to the clinical market, enabling the use of blood and other bodily fluids for more effective and patient-friendly diagnosis, monitoring, and treatment of cancer. MX-ICP improves the ability to detect genetic mutations by 100 - 400 fold over existing technologies. This technology has been validated internally on all currently available sequencing platforms, including Sanger, Next Gen Sequencing, and Digital PCR.

Type
Public
HQ
Omaha, US
Founded
1997
Size (employees)
19 (est)
Precipio was founded in 1997 and is headquartered in Omaha, US
Report incorrect company information

Precipio Office Locations

Precipio has offices in Omaha and New Haven
Omaha, US (HQ)
12325 Emmet St
New Haven, US
5 Science Park
Show all (2)
Report incorrect company information

Precipio Financials and Metrics

Precipio Financials

Precipio's revenue was reported to be $1.72 m in FY, 2017
USD

Revenue (FY, 2017)

1.7 m

Gross profit (FY, 2017)

292 k

Gross profit margin (FY, 2017), %

16.9%

Net income (FY, 2017)

(20.7 m)

EBIT (FY, 2017)

(15.5 m)

Market capitalization (24-Oct-2017)

1.2 m

Cash (31-Dec-2017)

421 k

EV

1.3 m
Precipio's current market capitalization is $1.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

27.5 m27.1 m1.7 m1.6 m1.7 m

Revenue growth, %

(2%)(94%)(6%)

Cost of goods sold

15 m17.4 m1.9 m1.8 m1.4 m

Gross profit

12.5 m9.7 m(287 k)(205 k)292 k
Quarterly
USDQ3, 2017

Revenue

270 k

Operating expense total

3.6 m

EBIT

(3.6 m)

EBIT margin, %

(1346%)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.6 m1.6 m444 k110 k421 k

Accounts Receivable

5.3 m7.6 m264 k225 k730 k

Inventories

4 m3 m24 k161 k

Current Assets

11.8 m13.4 m3.3 m495 k1.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

4 m1.7 m1.2 m880 k5.4 m2.3 m2.8 m222 k421 k71 k59 k967 k381 k

Accounts Receivable

4.4 m6.2 m7.3 m7.5 m8.3 m9.7 m9.3 m170 k328 k180 k279 k569 k505 k

Inventories

4.5 m4.1 m4 m3.6 m3 m2.6 m44 k39 k36 k15 k108 k99 k

Current Assets

14.2 m12.7 m13.4 m13.7 m18.2 m15.5 m16.1 m2.1 m1.8 m866 k567 k1.8 m1.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16 m)(13.9 m)(33 m)(7.6 m)(20.7 m)

Depreciation and Amortization

2.7 m2.2 m489 k262 k743 k

Inventories

908 k715 k(113 k)26 k(46 k)

Accounts Payable

801 k2 m(365 k)3.1 m500 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Inventories

15 k

Accounts Payable

3.5 m3.4 m5 m4.7 m3.7 m5 m5.6 m6.3 m8.5 m
USDY, 2017

EV/EBIT

-0.1 x

EV/CFO

-0.2 x

Revenue/Employee

68.9 k
Show all financial metrics
Report incorrect company information